

# LITERATURA

Al-Tawfiq JA, Laxminarayan R, Mendelson M. How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals? *Int J Infect Dis* 2017; 54: 77–84.

Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. *Clin Infect Dis* 2007; 44: 79–86.

Anderson RJ, Groundwater PW, Todd A, Worsley A. *Antibacterial agents: chemistry, mode of action, mechanisms of resistance and clinical applications*. Chichester: Wiley 2012.

Baltz RH, Miao V, Wrigley SK. Natural products to drugs: daptomycin and related lipopeptide antibiotics. *Nat Prod Rep* 2005; 22: 717–741.

Bartlett JG (ed). *The Johns Hopkins POC-IT ABX guide*. [online] <http://www.hopkins-guides.com>

Beneš J (ed). *Infekční lékařství*. Praha: Galén 2009.

Bennett JE, Dolin R, Blaser MJ (eds). *Mandell, Douglas and Benett's principles and practice of infectious diseases*. 8<sup>th</sup> ed. Philadelphia: Elsevier Saunders 2015.

Bo G. Giuseppe Brotzu and the discovery of cephalosporins. *Clin Microbiol Infect* 2000; 6 (Suppl 3): 6–9.

Brodt HR. *Antibiotika-Therapie. Klinik und Praxis der antiinfektiösen Behandlung*. Stuttgart: Schattauer 2013.

Bruss JB. Lack of evidence associating nephrotoxicity with low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis. *Clin Infect Dis* 2009; 49: 806.

Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. *J Antibiot (Tokyo)* 2014; 67: 667–670.

Cosgrove SE, Vigliani GA, Fowler VG jr, et al. Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis* 2009; 46: 713–721.

Craig WA, Kunin CM. Significance of serum protein and tissue binding of antimicrobial agents. *Annu Rev Med* 1976; 27: 287–300.

Crotty MP, Krekel T, Burnham CA, Ritchie DJ. New gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides. *J Clin Microbiol* 2016; 54: 2225–2232.

Čivljak R, Giannella M, Di Bella S, Petrosillo N. Could chloramphenicol be used against

- ESKAPE pathogens? A review of *in vitro* data in the literature from the 21<sup>st</sup> century. *Expert Rev Anti Infect Ther* 2014; 12: 249–264.
- Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 2010; 74: 417–433.
- Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. *Clin Infect Dis* 2010; 50 (Suppl 1): S10–S15.
- Garner D. Microbiology nuts and bolts. Key concepts of microbiology and infection. CreateSpace 2013.
- Garrod LP. L.P. Garrod on antibiotics. A selection of his *British Medical Journal* editorials. *J Antimicrob Chemother* 1985; 15 (Suppl B): 1–46.
- Gilbert DN (ed). Sanford guide web edition. [online] [www.sanfordguide.com/products/digital-subscriptions/web-edition](http://www.sanfordguide.com/products/digital-subscriptions/web-edition)
- Gold HS, Moellering RC, jr. Antimicrobial-drug resistance. *N Engl J Med* 1996; 335: 1445–1453.
- Greenwood D. Antimicrobial drugs. Chronicle of a twentieth century medical triumph. New York: Oxford University Press 2008.
- Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. *Pharmacotherapy* 2010; 30: 80–94.
- Hejzlar M. Antibiotika v praxi. Praha: Galén 1995.
- Chen TC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. *Int J Infect Dis* 2011; 15: e211–e216.
- Jelić D, Antolović R. From erythromycin to azithromycin and new potential ribosome-binding antimicrobials. *Antibiotics (Basel)* 2016; 5: E29; doi:10.3390/antibiotics5030029.
- Jindrák V, Hedlová D, Urbášková P, et al. Antibiotická politika a prevence infekcí v nemocnici. Praha: Mladá fronta 2014.
- Karaiskos I, Souli M, Galani I, Giamarellou H. Colistin: still a lifesaver for the 21<sup>st</sup> century? *Expert Opin Drug Metab Toxicol* 2017; 13: 59–71.
- Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. *Expert Opin Investig Drugs* 2007; 16: 717–733.
- Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. *J Infect Chemother* 2002; 8: 125–133.
- Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. *Mayo Clin Proc* 2011; 86: 156–167.
- Levine DP. Vancomycin: a history. *Clin Infect Dis* 2006; 42 (Suppl 1): S5–S12.
- Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. *Infect Dis Clin North Am* 2009; 23: 791–815.
- Llewelyn MJ, Fitzpatrick JM, Daewin E, et al. The antibiotic course has had its day. *Br Med J* 2017; 358: j3418.
- Lochmann O. Antimikrobní terapie v praxi. Praha: Triton 2006.

- Macy E, Romano A, Khan D. Practical management of antibiotic hypersensitivity in 2017. *J Allergy Clin Immunol Pract* 2017; 5: 577–586.
- Mascaretti OA. Bacteria versus antibacterial agents: an integrated approach. Washington, DC: ASM Press 2003.
- McKenzie C. Antibiotic dosing in critical illness. *J Antimicrob Chemother* 2011; 66 (Suppl 2): ii25–ii31.
- Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive guidance for antibiotic dosing in obese adults. *Pharmacotherapy* 2017; 37: 1415–1431.
- Moellering RC Jr. Vancomycin: a 50-year reassessment. *Clin Infect Dis* 2006; 42 (Suppl 1): S3–4.
- Nasr I, Al Wahshi HA, Al Wahshi AA, Lukawska J. Antibiotic allergy, when to test, challenge or desensitise. *J Med Microb Diagn* 2016; 5: 234; doi:10.4172/2161-0703.1000234.
- Nelson ML, Levy SB. The history of the tetracyclines. *Ann N Y Acad Sci* 2011; 1241: 17–32.
- Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. *J Antimicrob Chemother* 2015; 70: 382–395.
- Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. *Clin Infect Dis* 2004; 38: 864–870.
- Rybak M. The pharmacokinetic and pharmacodynamic properties of vancomycin. *Clin Infect Dis* 2006; 42 (Suppl 1): S35–S39.
- Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm* 2009; 66: 82–98.
- Scarpa B. Homage from one Sardinian to another. *Clin Microbiol Infect* 2000; 6 (Suppl 3): 3–5.
- Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or ceftazolin versus vancomycin in methicillin-susceptible *Staphylococcus aureus* bacteremia. *BMC Infect Dis* 2011; 11: 279.
- Silver LL, Bush K. Antibiotics and antibiotic resistance. New York: Cold Spring Harbor Laboratory Press 2016.
- Sköld O. Sulfonamides and trimethoprim. *Expert Rev Anti Infect Ther* 2010; 8: 1–6.
- Southwick F. Infectious diseases: a clinical short course. 3<sup>rd</sup> ed. New York: McGraw-Hill Education 2014.
- Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. *Clin Liver Dis* 2013; 17: 609–642.
- Sykes RB. From moulds to drugs. *Clin Microbiol Infect* 2000; 6 (Suppl 3): 10–12.
- Špízek J, Řezanka T. Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. *Biochem Pharmacol* 2017; 133: 20–28.

Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. *J Antimicrob Chemother* 2000; 46: 523–526.

Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. *Bioorg Med Chem* 2016; 24: 6409–6419.

Vacek V, Hejzlar M, et al. *Chemoterapie infekčních nemocí v klinické praxi*. Praha: Avicenum 1988.

Van Bambeke F. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. *Drugs* 2015; 75: 2073–2095.

Van Miert AS. The sulfonamide-diaminopyrimidine story. *J Vet Pharmacol Ther* 1994; 17: 309–316.

Vokurka M, Hugo J, et al. *Velký lékařský slovník*. 6. vyd. Praha: Maxdorf 2006.

Walsh C, Wencewicz TA. *Antibiotics: challenges, mechanism, opportunities*. Washington, DC: ASM Press 2016.

Weinstein L, Dalton AC. Host determinants of response to antimicrobial agents. *N Engl J Med* 1968; 279: 524–531.

Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. *Drugs* 2016; 76: 567–588.

Zinner SH. Antibiotic use: present and future. *New Microbiol* 2007; 30: 321–325.